Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies
A. Papi (Ferrara, Italy), D. Singh (Manchester, United Kingdom), C. Virchow (Rostock, Germany), M. Kots (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), G. Canonica (Milan, Italy)
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Papi (Ferrara, Italy), D. Singh (Manchester, United Kingdom), C. Virchow (Rostock, Germany), M. Kots (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), G. Canonica (Milan, Italy). Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies. 2637
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019
Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008
LATE-BREAKING ABSTRACT: Association of incident pneumonia and exacerbations with extrafine beclometasone dipropionate/formoterol (BDP/FF) in severe COPD patients: A post-hoc analysis of FORWARD study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004
Extrafine beclometasone dipropionate, formoterol fumarate, glycopyrronium (BDP/FF/G) and exacerbation recurrence: post-hoc analysis of the TRIBUTE study. Source: International Congress 2018 – COPD management Year: 2018
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Cost-effectiveness of fluticasone/salmeterol inhaler in treatment of moderate and severe bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Effects of budesonide/formoterol combination therapy versus budesonide on airway dimensions in asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: an exploratory analysis of the RELIEF study in patients using formoterol as maintenance therapy Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001
Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008